New AIDS Clinical Trials Unit Study Opens
December 30, 2003
ACTG Study 5142A study to compare the effectiveness of three regimens for the initial treatment of HIV Infection
The study will examine the use of a lopinavir/ritonavir (a ritonavir-enhanced, second generation protease inhibitor)-based regimen, a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen, and a nucleoside-sparing regimen as the first treatment of HIV-1 infection.
The study will last for about three years.
Exams and lab tests provided at no cost. Only TDF, EFV, LPV/r, and d4tXR will be provided by the study.
Subjects receive $20 per study visit.
Contact Alyssa or Lori at the ACTU at (206) 731-3184.
This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Ezine.